Dumez H - Search Results

1

In vitro partition of irinotecan (CPT-11) in human volunteer blood: the influence of concentration, gender and smoking.

Dumez H, Guetens G, De Boeck G, Highley MS, de Bruijn EA, van Oosterom AT, Maes RA. Dumez H, et al. Anticancer Drugs. 2005 Sep;16(8):893-5. doi: 10.1097/01.cad.0000175584.86198.ac. Anticancer Drugs. 2005. PMID: 16096439

2

Altered irinotecan metabolism in a patient receiving phenytoin.

Mathijssen RH, Sparreboom A, Dumez H, van Oosterom AT, de Bruijn EA. Mathijssen RH, et al. Among authors: dumez h. Anticancer Drugs. 2002 Feb;13(2):139-40. doi: 10.1097/00001813-200202000-00004. Anticancer Drugs. 2002. PMID: 11901305

3

The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment.

Dumez H, Guetens G, De Boeck G, Highley MS, Maes RA, van Oosterom AT, de Bruijn EA. Dumez H, et al. Clin Chem Lab Med. 2004;42(11):1219-27. doi: 10.1515/CCLM.2004.244. Clin Chem Lab Med. 2004. PMID: 15576286 Review.

4

In vitro partition of docetaxel and gemcitabine in human volunteer blood: the influence of concentration and gender.

Dumez H, Guetens G, De Boeck G, Highley MS, de Bruijn EA, van Oosterom AT, Maes RA. Dumez H, et al. Anticancer Drugs. 2005 Sep;16(8):885-91. doi: 10.1097/01.cad.0000175585.24317.ca. Anticancer Drugs. 2005. PMID: 16096438

5

Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study.

Dumez H, Martens M, Selleslach J, Guetens G, De Boeck G, Aerts R, De Bruijn EA, Maes RA, van Oosterom AT. Dumez H, et al. Anticancer Drugs. 2007 Feb;18(2):211-8. doi: 10.1097/CAD.0b013e328010ee5c. Anticancer Drugs. 2007. PMID: 17159607 Clinical Trial.

6

A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.

Dumez H, Awada A, Piccart M, Assadourian S, Semiond D, Guetens G, de Boeck G, Maes RA, de Bruijn EA, van Oosterom A. Dumez H, et al. Ann Oncol. 2006 Jul;17(7):1158-65. doi: 10.1093/annonc/mdl071. Epub 2006 Apr 6. Ann Oncol. 2006. PMID: 16600980 Free article. Clinical Trial.

7

The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.

Dumez H, Louwerens M, Pawinsky A, Planting AS, de Jonge MJ, Van Oosterom AT, Highley M, Guetens G, Mantel M, de Boeck G, de Bruijn E, Verweij J. Dumez H, et al. Anticancer Drugs. 2002 Jul;13(6):583-93. doi: 10.1097/00001813-200207000-00004. Anticancer Drugs. 2002. PMID: 12172503 Clinical Trial.

8

Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry.

Guetens G, De Boeck G, Highley M, Dumez H, Van Oosterom AT, de Bruijn EA. Guetens G, et al. Among authors: dumez h. J Chromatogr A. 2003 Dec 5;1020(1):27-34. doi: 10.1016/s0021-9673(03)00775-1. J Chromatogr A. 2003. PMID: 14661754

9

Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study.

D'hondt R, Paridaens R, Wildiers H, Pauwelyn K, Thomas J, Dumez H, Van Oosterom AT. D'hondt R, et al. Among authors: dumez h. Anticancer Drugs. 2004 Apr;15(4):341-6. doi: 10.1097/00001813-200404000-00005. Anticancer Drugs. 2004. PMID: 15057137 Clinical Trial.

10

Human red blood cells: rheological aspects, uptake, and release of cytotoxic drugs.

Dumez H, Reinhart WH, Guetens G, de Bruijn EA. Dumez H, et al. Crit Rev Clin Lab Sci. 2004;41(2):159-88. doi: 10.1080/10408360490452031. Crit Rev Clin Lab Sci. 2004. PMID: 15270553 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

98 results

Search Page